In 21 NPM1-mutated AML patients with available post-induction NPM1c transcript MRD data, MRD levels did not differ between patients with chemosensitive versus chemoresistant blasts (p = 0.35). This evidence concerns the gene NPM1 and acute myeloid leukemia.